

d			
ä	Variants	<b>S309</b> IC50(µg/ml)	2B04 IC50(µg/ml)
	D614G	0.13±0.03	0.01±0.00
	BA.2	0.41±0.08	>12
	XBB.1.5	0.30±0.13	>12
	BA.2.86	6.22±1.35	>12
	JN.1	>12	>12
	BA.2.87.1	0.62±0.30	>12
e	Relative infection (%) 140 - 140 - 00 100 - 08 - 00 - 09 - 00 - 00 - 00		<ul> <li>D614G</li> <li>BA.2</li> <li>XBB.1.5</li> <li>BA.2.86</li> <li>JN.1</li> <li>BA.2.87.1</li> </ul>

-2 -1 0 Log₁₀ 2B04 concentration

1

-3

FIG S1 Heatmap display of nAb escape in three cohorts. NAb tiers against BA.2.87.1, BA.2.86, JN.1, XBB.1.5, BA.2 and ancestral D614G shown in Figs. 2a-c are respectively displayed as heat maps for sera from health care workers (HCWs) (n = 13) (a), for sera from first-responder/household Columbus contact cohort (P1 to P5) and ICU patients admitted to OSU Wexner Medical Center (P6 to P9) (total n=9) during when the BA.2.86/JN.1 variants were predominantly circulating in Columbus, Ohio (b), and for sera from Golden Syrian hamsters inoculated with 2 doses of monovalent XBB.1.5 vaccine (1.5 x 10<sup>5</sup> PFU per hamster, n=15), with blood being collected 5 weeks after inoculation (c). The neutralization assays were also performed to assess the effectiveness of mAbs S309 and 2B04 in neutralizing SARS-CoV-2 variants (d-e). The calculated IC50 values (means standard deviation are shown (d). The  $\pm$ neutralization curves of 2B04 were shown in (e).



## 293T/ACE2



